Adaptive Biotechnologies Corp. (ADPT)
15.39
-0.03
(-0.19%)
USD |
NASDAQ |
Dec 12, 10:40
Adaptive Biotechnologies Cash from Investing (Quarterly): 17.28M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Akero Therapeutics, Inc. | 56.78M |
| Ionis Pharmaceuticals, Inc. | 91.34M |
| Regeneron Pharmaceuticals, Inc. | -402.90M |
| Vertex Pharmaceuticals, Inc. | -117.00M |
| Ultragenyx Pharmaceutical, Inc. | 117.18M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -7.127M |
| Cash from Financing (Quarterly) | 1.684M |
| Free Cash Flow | -62.94M |
| Free Cash Flow Per Share (Quarterly) | -0.0462 |
| Free Cash Flow to Equity (Quarterly) | -3.242M |
| Free Cash Flow to Firm (Quarterly) | -4.565M |
| Free Cash Flow Yield | -2.67% |